Back to Agenda
Session 1 Track 2: Current and Emerging Technologies
Session Chair(s)
Keith Wenzel
Volunteer
DIA Study Endpoints Community, United States
Despite being a risk adverse industry, the Life Sciences Industry currently has a stable of tried and true technologies which have been embraced and generate value, but we find ourselves beset by literal barrage of new technologies some of which show signs of promise, some where the jury is still out and others yet untested, but intriguing. This session will include two presentations on Current and Emerging Technologies followed by a panel discussing the state of play for digital technology and the trends and concepts around the next generation of tried and true technologies as well as the potential benefits of emerging technology.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand how currently accepted and adopted technology is evolving to deliver additional benefits
- Have a view to emerging technologies and their respective place along the adoption curve
Speaker(s)
Speaker
Stephen Ruhmel, MPH
Janssen Research & Development, United States
Clinical Innovation Lead
Speaker
Keith Wenzel
DIA Study Endpoints Community, United States
Volunteer
Panelist
Paul Upham
Roche / Genentech, United States
Head, Smart Devices
Bill Byrom, PhD
Bill Byrom, PhD
Signant Health , United Kingdom
Vice President, Product Intelligence and Positioning; Principal, eCOA Science
Have an account?